JP5869701B2 - アミジン置換β−ラクタム化合物類、それらの調製及び抗菌剤 - Google Patents

アミジン置換β−ラクタム化合物類、それらの調製及び抗菌剤 Download PDF

Info

Publication number
JP5869701B2
JP5869701B2 JP2014553696A JP2014553696A JP5869701B2 JP 5869701 B2 JP5869701 B2 JP 5869701B2 JP 2014553696 A JP2014553696 A JP 2014553696A JP 2014553696 A JP2014553696 A JP 2014553696A JP 5869701 B2 JP5869701 B2 JP 5869701B2
Authority
JP
Japan
Prior art keywords
amino
thiazol
imino
ethoxy
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014553696A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015504907A (ja
Inventor
クレンケ ブルクハルト
クレンケ ブルクハルト
ビーガント イリト
ビーガント イリト
シファー グイド
シファー グイド
ブレッツ−エスター−ヘルト ハイケ
ブレッツ−エスター−ヘルト ハイケ
エヌ.マイティ サマレンドラ
エヌ.マイティ サマレンドラ
カーン ジェハンガー
カーン ジェハンガー
レディ アンデ
レディ アンデ
ヤン チーシャン
ヤン チーシャン
ヘナ モスタファ
ヘナ モスタファ
チア クオフォン
チア クオフォン
リゴン オウ
リゴン オウ
リアン ホン
リアン ホン
イップ ジュディ
イップ ジュディ
ガオ チュワンジュン
ガオ チュワンジュン
タジャムル サビア
タジャムル サビア
モハマッド ラヒム
モハマッド ラヒム
ビスワジェット ガングリ
ビスワジェット ガングリ
Original Assignee
アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト
アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト, アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト filed Critical アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト
Publication of JP2015504907A publication Critical patent/JP2015504907A/ja
Application granted granted Critical
Publication of JP5869701B2 publication Critical patent/JP5869701B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2014553696A 2012-01-24 2013-01-23 アミジン置換β−ラクタム化合物類、それらの調製及び抗菌剤 Expired - Fee Related JP5869701B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12152279 2012-01-24
EP12152279.1 2012-01-24
PCT/EP2013/051217 WO2013110643A1 (en) 2012-01-24 2013-01-23 Amidine substituted beta - lactam compounds, their preparation and use as antibacterial agents

Publications (2)

Publication Number Publication Date
JP2015504907A JP2015504907A (ja) 2015-02-16
JP5869701B2 true JP5869701B2 (ja) 2016-02-24

Family

ID=47603723

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014553696A Expired - Fee Related JP5869701B2 (ja) 2012-01-24 2013-01-23 アミジン置換β−ラクタム化合物類、それらの調製及び抗菌剤

Country Status (43)

Country Link
US (2) US9556165B2 (US07928230-20110419-C00014.png)
EP (1) EP2806873B1 (US07928230-20110419-C00014.png)
JP (1) JP5869701B2 (US07928230-20110419-C00014.png)
KR (1) KR102036393B1 (US07928230-20110419-C00014.png)
CN (1) CN104203237A (US07928230-20110419-C00014.png)
AP (1) AP2014007880A0 (US07928230-20110419-C00014.png)
AR (1) AR089796A1 (US07928230-20110419-C00014.png)
AU (1) AU2013211575B2 (US07928230-20110419-C00014.png)
BR (1) BR112014017968A8 (US07928230-20110419-C00014.png)
CA (1) CA2862338C (US07928230-20110419-C00014.png)
CL (1) CL2014001956A1 (US07928230-20110419-C00014.png)
CO (1) CO7101240A2 (US07928230-20110419-C00014.png)
CU (1) CU24273B1 (US07928230-20110419-C00014.png)
CY (1) CY1117955T1 (US07928230-20110419-C00014.png)
DK (1) DK2806873T3 (US07928230-20110419-C00014.png)
EA (1) EA027126B1 (US07928230-20110419-C00014.png)
EC (1) ECSP14010249A (US07928230-20110419-C00014.png)
ES (1) ES2592403T3 (US07928230-20110419-C00014.png)
HK (1) HK1203389A1 (US07928230-20110419-C00014.png)
HR (1) HRP20161171T1 (US07928230-20110419-C00014.png)
HU (1) HUE030452T2 (US07928230-20110419-C00014.png)
IL (1) IL233805A (US07928230-20110419-C00014.png)
IN (1) IN2014MN01640A (US07928230-20110419-C00014.png)
LT (1) LT2806873T (US07928230-20110419-C00014.png)
MA (1) MA35905B1 (US07928230-20110419-C00014.png)
ME (1) ME02532B (US07928230-20110419-C00014.png)
MX (1) MX346602B (US07928230-20110419-C00014.png)
MY (1) MY173843A (US07928230-20110419-C00014.png)
NZ (1) NZ626951A (US07928230-20110419-C00014.png)
PE (1) PE20142345A1 (US07928230-20110419-C00014.png)
PH (1) PH12014501671B1 (US07928230-20110419-C00014.png)
PL (1) PL2806873T3 (US07928230-20110419-C00014.png)
PT (1) PT2806873T (US07928230-20110419-C00014.png)
RS (1) RS55210B1 (US07928230-20110419-C00014.png)
SG (1) SG11201403930XA (US07928230-20110419-C00014.png)
SI (1) SI2806873T1 (US07928230-20110419-C00014.png)
SM (1) SMT201600354B (US07928230-20110419-C00014.png)
TN (1) TN2014000297A1 (US07928230-20110419-C00014.png)
TW (1) TWI659953B (US07928230-20110419-C00014.png)
UA (1) UA110880C2 (US07928230-20110419-C00014.png)
UY (1) UY34585A (US07928230-20110419-C00014.png)
WO (1) WO2013110643A1 (US07928230-20110419-C00014.png)
ZA (1) ZA201405057B (US07928230-20110419-C00014.png)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015103583A1 (en) * 2014-01-06 2015-07-09 President And Fellows Of Harvard College Monobactams and methods of their synthesis and use
AU2015236369B2 (en) 2014-03-24 2017-02-16 Novartis Ag Monobactam organic compounds for the treatment of bacterial infections
CN105175335B (zh) * 2015-08-13 2017-11-03 南阳师范学院 一种3‑(3,3‑二氯烯丙氧基)‑1‑甲基吡唑‑5‑甲酰胺衍生物及其制备方法
AU2016327264B2 (en) 2015-09-23 2019-06-27 Novartis Ag Salts and solid forms of monobactam antibiotic
EP3390357B1 (en) * 2015-12-15 2021-11-10 Merck Sharp & Dohme Corp. Biaryl monobactam compounds for the treatment of bacterial infections
MX2018010878A (es) 2016-03-07 2018-11-09 Merck Sharp & Dohme Compuestos de aril-monobactam biciclicos y metodos de uso de los mismos para el tratamiento de infecciones bacterianas.
CN107641119B (zh) 2016-07-21 2019-11-08 中国科学院上海药物研究所 单环β-内酰胺-铁载体轭合物及其制备方法和用途
EP4223766A3 (en) 2016-08-26 2023-10-18 Codexis, Inc. Engineered imine reductases and methods for the reductive amination of ketone and amine compounds
JP2019535724A (ja) 2016-11-18 2019-12-12 アイキュリス アンチ−インフェクティブ キュアズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 細菌感染症の治療に使用するためのアミジン置換β−ラクタム化合物のリポソーム製剤
EP3541364A1 (en) 2016-11-18 2019-09-25 AiCuris Anti-infective Cures GmbH Novel formulations of amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and acidifying agents, their preparation and use as antimicrobial pharmaceutical compositions
BR112019012994A2 (pt) * 2016-12-21 2019-12-03 Aicuris Gmbh & Co Kg terapia de combinação com compostos de b-lactama de amidina substituída e inibidores de b-lactamase para infecções com cepas bacterianas resistentes a antibiótico
AU2018304841A1 (en) 2017-07-18 2020-02-06 Bayer Aktiengesellschaft Substituted 3-heteroaryloxy-1H-pyrazoles and salts thereof and their use as herbicidal active substances
WO2019020810A1 (en) 2017-07-28 2019-01-31 Aicuris Anti-Infective Cures Gmbh CRYSTALLINE FORM OF (2S) -2 - [[(Z) - [- 1- (2-AMINO-4-THIAZOLYL) -2 - [[(3S) -2,2-DIMETHYL-4-OXO] -Acid 1- (SULFOOXY) -3-AZETIDINYL] AMINO] -2-OXOETHYLIDENE] AMINO] OXY] -3- [4- [IMINO [(3R) -3-PIPERIDINYLAMINO] METHYL] PHENOXY] -PROPANOIC
US11414411B2 (en) 2017-08-02 2022-08-16 Novartis Ag Chemical process for manufacturing monobactam antibiotic and intermediates thereof
CA3076022C (en) 2017-10-02 2023-01-17 Merck Sharp & Dohme Corp. Chromane monobactam compounds for the treatment of bacterial infections
KR102455390B1 (ko) * 2017-10-02 2022-10-17 아릭사 파마슈티컬스 인코포레이티드 아즈트레오남 유도체 및 이의 용도
US11459323B2 (en) 2018-01-29 2022-10-04 Medshine Discovery Inc. Monocyclic β-lactam compound for treating bacterial infection
EP3882246A4 (en) * 2018-11-13 2021-12-29 Nanjing Sanhome Pharmaceutical Co., Ltd. Monobactam compounds and use therefor
WO2020125670A1 (zh) 2018-12-18 2020-06-25 南京明德新药研发有限公司 单环β-内酰胺化合物在制药中的应用
CN111303144B (zh) * 2019-12-13 2020-11-27 苏州信诺维医药科技有限公司 一种治疗细菌感染的化合物
EP4079305A4 (en) 2019-12-19 2024-01-10 Shenzhen Optimum Biological Technology Co., Ltd APPLICATION OF A COMPOUND IN THE PREPARATION OF DRUG
CN111253405B (zh) * 2020-03-20 2022-12-16 南京安伦化工科技有限公司 一种比阿培南中间体的制备方法
CN111675641B (zh) * 2020-06-04 2023-09-08 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) 单环β-内酰胺类化合物、单环内酰胺类化合物盐及其制备方法
CN111592536B (zh) * 2020-06-04 2023-11-03 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) 单环β-内酰胺化合物及其制备方法和应用
US20230295149A1 (en) * 2020-07-16 2023-09-21 Ningxia Academy Of Agriculture And Forestry Sciences Monobactam compounds, their preparation and use as antibacterial agents
US20230150996A1 (en) * 2020-08-06 2023-05-18 Ningxia Academy Of Agriculture And Forestry Sciences B-lactam compounds, their preparation and use as antibacterial agents
CN112079791A (zh) * 2020-08-21 2020-12-15 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) 单环β-内酰胺类抗生素侧链酸及其酯、其制备方法和应用
CN111909067B (zh) * 2020-08-28 2022-03-15 浙江凯普化工有限公司 一种d-青霉胺的有机全合成方法
WO2023082055A1 (zh) * 2021-11-09 2023-05-19 中国医学科学院医药生物技术研究所 包含β-内酰胺类化合物的药物组合物及其用途
KR20240105442A (ko) 2021-11-18 2024-07-05 머크 샤프 앤드 돔 엘엘씨 크로만 아미딘 모노박탐 항생제

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794886A (fr) * 1972-02-22 1973-08-02 Pfizer Acides 6-(alpha-(omega-guanidinoalcanoylamino)acylamino)-penicillaniques
DE2458973A1 (de) * 1974-12-13 1976-06-16 Hoechst Ag Acylaminopenicillansaeuren und verfahren zu ihrer herstellung
DE2749265A1 (de) 1977-11-03 1979-05-10 Linde Ag Verfahren zur biologischen reinigung von abwasser
ZA806977B (en) * 1979-11-19 1981-10-28 Fujisawa Pharmaceutical Co 7-acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof
JPS58210061A (ja) * 1982-05-31 1983-12-07 Takeda Chem Ind Ltd 1−スルホ−2−オキソアゼチジン誘導体、その製造法および用途
CA1262128A (en) 1981-08-27 1989-10-03 Christian N. Hubschwerlen .beta.-lactams
NZ205642A (en) 1982-10-06 1986-08-08 Squibb & Sons Inc Beta-lactams and pharmaceutical compositions
US4638060A (en) 1985-04-29 1987-01-20 E. R. Squibb & Sons, Inc. O-sulfated spiro β-lactam hydroxamic acids
EP0336667A3 (en) 1988-04-04 1991-04-10 E.R. Squibb & Sons, Inc. [3S(Z)]-3-[[(2-amino-4-thiazolyl)[[2-(hydroxyamino)-2-oxoethoxy]imino]acetyl]-amino]-2,2-dimethyl-4-oxo-1-azetidinyl sulfate
US5112968A (en) 1989-07-28 1992-05-12 E. R. Squibb & Sons, Inc. Monobactam hydrazide derivatives
CA2024282A1 (en) 1989-09-21 1991-03-22 Peter H. Ermann Heterocyclic hydrazide derivatives of monocyclic beta-lactam antibiotics
ZA918014B (en) 1990-11-05 1992-07-29 Squibb & Sons Inc Heteroaroyl derivatives of monocyclic beta-lactam antibiotics
US5250691A (en) 1991-09-09 1993-10-05 E. R. Squibb & Sons, Inc. Heteroaryl derivatives of monocyclic beta-lactam antibiotics
US5994340A (en) 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
AU1261402A (en) 2000-09-14 2002-03-26 Naeja Pharmaceutical Inc 3-(heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents
CN1914151A (zh) 2004-01-27 2007-02-14 默克弗罗斯特公司 作为环氧合酶-2抑制剂的二芳基-2(5h)-呋喃酮类的释放一氧化氮的前药
NZ567629A (en) 2005-09-23 2011-08-26 Ms Science Corp Piperazine derivatives useful in the treatment of discorders of the central nervous system
CN103724330B (zh) * 2005-12-07 2015-08-19 巴斯利尔药物股份公司 单环-内酰胺类抗生素与β-内酰胺酶抑制剂的有效的联合应用
UA90940C2 (ru) 2006-02-14 2010-06-10 Ихара Кемикал Индастри Ко., Лтд. Способ получения соединений 5-алкокси-4-гидроксиметилпиразола и соединения 5-алкокси-4-гидроксиметилпиразола
JP2009530228A (ja) 2006-03-16 2009-08-27 アステラス製薬株式会社 セフェム化合物および抗菌薬としての利用
WO2008116813A2 (en) 2007-03-23 2008-10-02 Basilea Pharmaceutica Ag Combination medicaments for treating bacterial infections
WO2009049028A1 (en) 2007-10-09 2009-04-16 Targegen Inc. Pyrrolopyrimidine compounds and their use as janus kinase modulators
CN102325769A (zh) 2008-12-19 2012-01-18 美国辉瑞有限公司 单卡波姆

Also Published As

Publication number Publication date
EP2806873B1 (en) 2016-06-15
HK1203389A1 (zh) 2015-10-30
JP2015504907A (ja) 2015-02-16
CA2862338C (en) 2019-04-16
PE20142345A1 (es) 2015-01-09
BR112014017968A8 (pt) 2017-07-11
AU2013211575A1 (en) 2014-07-24
TWI659953B (zh) 2019-05-21
AU2013211575B2 (en) 2017-03-02
CO7101240A2 (es) 2014-10-31
ES2592403T3 (es) 2016-11-30
TW201343643A (zh) 2013-11-01
EA027126B1 (ru) 2017-06-30
CU20140090A7 (es) 2014-12-26
IL233805A (en) 2016-06-30
MX2014008915A (es) 2014-08-26
US9782390B2 (en) 2017-10-10
KR102036393B1 (ko) 2019-10-24
SG11201403930XA (en) 2014-08-28
SMT201600354B (it) 2016-11-10
LT2806873T (lt) 2016-10-10
MY173843A (en) 2020-02-24
RS55210B1 (sr) 2017-01-31
MX346602B (es) 2017-03-24
CN104203237A (zh) 2014-12-10
CA2862338A1 (en) 2013-08-01
US20150045340A1 (en) 2015-02-12
ZA201405057B (en) 2017-09-27
SI2806873T1 (sl) 2016-10-28
PH12014501671A1 (en) 2014-11-10
MA35905B1 (fr) 2014-12-01
NZ626951A (en) 2016-03-31
PH12014501671B1 (en) 2014-11-10
HRP20161171T1 (hr) 2016-11-04
TN2014000297A1 (en) 2015-12-21
EP2806873A1 (en) 2014-12-03
AR089796A1 (es) 2014-09-17
AP2014007880A0 (en) 2014-08-31
IL233805A0 (en) 2014-09-30
WO2013110643A1 (en) 2013-08-01
DK2806873T3 (en) 2016-08-29
KR20140114390A (ko) 2014-09-26
US9556165B2 (en) 2017-01-31
CY1117955T1 (el) 2017-05-17
ME02532B (me) 2017-02-20
BR112014017968A2 (US07928230-20110419-C00014.png) 2017-06-20
PT2806873T (pt) 2016-09-23
HUE030452T2 (en) 2017-05-29
UY34585A (es) 2013-09-02
UA110880C2 (uk) 2016-02-25
CL2014001956A1 (es) 2014-11-07
PL2806873T3 (pl) 2016-12-30
EA201400838A1 (ru) 2014-12-30
US20170100379A1 (en) 2017-04-13
ECSP14010249A (es) 2015-12-31
IN2014MN01640A (US07928230-20110419-C00014.png) 2015-05-22
CU24273B1 (es) 2017-08-08

Similar Documents

Publication Publication Date Title
JP5869701B2 (ja) アミジン置換β−ラクタム化合物類、それらの調製及び抗菌剤
US9511073B2 (en) Aromatic amides and uses thereof
CN114728953B (zh) β-内酰胺类化合物,及其制备方法以及其作为抗菌素的应用
KR20160108409A (ko) 질소 내포 화합물 및 항세균제로서 이들의 용도
JP2011500845A (ja) カルバセフェムβ−ラクタム抗生物質
TW202421162A (zh) 氧基取代化合物
US7001897B2 (en) 1-methylcarbapenem derivatives
CN115210231B (zh) 单环内酰胺类化合物、其制备方法及其作为抗菌药的用途
OA17341A (en) Amidine substituted beta - lactam compounds, their preparation and use as antibacterial agents.
CN114531850A (zh) 以含有新的青霉素衍生物或其盐以及选自β-内酰胺酶抑制化合物及抗菌性化合物或其盐中的1种以上的化合物为特征的医药组合物及试剂盒
CN111954673A (zh) 新型的青霉烷衍生物或其盐、医药组合物及其应用
JP7551186B2 (ja) ラクチビシン化合物、その調製、および抗菌剤としての使用
WO2001057041A1 (fr) Composes 1-methylcarbapedem

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150811

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151111

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151208

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160107

R150 Certificate of patent or registration of utility model

Ref document number: 5869701

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees